SECT Tech, LLC is an existing team of accomplished bioscience executives with complementary backgrounds and is part of the State of Connecticut’s CTNext economic development program (administered by Connecticut innovations) focused on identifying, advising and growing early stage life science, technology based companies and entrepreneurs. We currently have a client portfolio of approximately 50 life science, healthcare based companies.
Our approach is to “dig deep” with our clients, serving as their ad hoc Board of Directors, providing critical guidance in such key areas as assessment of their underlying technology, commercialization prospects, business model focus, potential customers, partners, and employees, facility space options and, of course, fund-raising effectiveness. Originally created with a Southeast Connecticut (SECT) focus in Q4, 2012, SECT Tech quickly became the “go-to” resource within the Connecticut’s statewide entrepreneurial life science community by working with companies, scientists, and entrepreneurs throughout the state, initially focused on the Groton / New London area but quickly expanding out to the New Haven (strong ties with Yale spin-outs), Farmington-Hartford, Stamford and Storrs (strong ties with UConn spin-outs) areas.
A brief description of our three principals follows:
- Harry H. Penner, Jr. – Life science CEO / entrepreneur – New Haven Pharmaceuticals, Marinus, Neurogen, Rib-X, Affinimark, Prevention, RxGen
- Julie Olson, Ph.D. – Former CEO of Mersana Therapeutics, VP at Pfizer – initially in a number of scientific capacities, then advancing to multiple Senior Licensing & Business Development roles
- Tom Gerson, MBA – Former CFO of life science start-ups … Intelligent MDx, HistoRx, CGI Pharmaceuticals, Director of Finance for Sanofi’s U.S. R & D Operations
For more information, please contact Tom Gerson: Teg6854@gmail.com